Body mass and DNA promoter methylation in breast tumors in the western New York exposures and breast cancer study

American Journal of Clinical Nutrition

Volumn 94, Issue 3, 2011, Pages 831-838

  Tao, Meng Hua ^a,b   Marian, Catalin ^c   Nie, Jing ^a   Ambrosone, Christine ^d   Krishnan, Shiva S ^c   Edge, Stephen B ^d   Trevisan, Maurizio ^a,e   Shields, Peter G ^c   Freudenheim, Jo L ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e UNIVERSITY OF NEVADA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PROTEIN P16; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR BETA 2; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; BREAST CANCER; CASE CONTROL STUDY; CHRONIC INFLAMMATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DNA METHYLATION; DNA MODIFICATION; FEMALE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OBESITY; POPULATION RESEARCH; POSTMENOPAUSE; PREMENOPAUSE; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; WAIST HIP RATIO; WEIGHT CHANGE;

ABDOMINAL FAT; ADULT; AGED; BODY MASS INDEX; BODY WEIGHT; BREAST NEOPLASMS; CADHERINS; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P16; HUMANS; LOGISTIC MODELS; MIDDLE AGED; NEW YORK; OBESITY, ABDOMINAL; ODDS RATIO; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PROMOTER REGIONS, GENETIC; RECEPTORS, RETINOIC ACID; WAIST-HIP RATIO;

EID: 80052020967     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.110.009365     Document Type: Article

References (48)

1. Feigelson H.S., Jonas C.R., Teras L.R., Thun M.J., Calle E.E. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 2004;13:220-4. (Pubitemid 38222552)
2. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-78. (Pubitemid 351232031)
3. Bianchini F., Kaaks R., Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 2002;3:565-74. (Pubitemid 34993644)
4. Calle E.E., Kaaks R. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-91. (Pubitemid 39025053)
5. Han D., Nie J., Bonner M.R., McCann S.E., Muti P., Trevisan M., Ramirez-Marrero F.A., Vito D., Freudenheim J.L. Lifetime adult weight gain, central adiposity, and the risk of pre- and postmenopausal breast cancer in the Western New York exposures and breast cancer study. Int J Cancer 2006;119:2931-7.
6. Adderley-Kelly B., Williams-Stephens E. The relationship between obesity and breast cancer. ABNF J 2003;14:61-5.
7. Harvie M., Hooper L., Howell A.H. Central obesity and breast cancer risk: A systematic review. Obes Rev 2003;4:157-73. (Pubitemid 36950578)
8. Friedenreich C.M. Review of anthropometric factors and breast cancer risk. Eur J Cancer Prev 2001;10:15-32. (Pubitemid 32200199)
9. Cleary M.P., Grossmann M.E. Minireview: Obesity and breast cancer: Obesity and breast cancerThe estrogen connection. Endocrinology 2009;150:2537-42.
10. Fernandez S.V., Russo J. Estrogen and xenoestrogens in breast cancer. Toxicol Pathol 2010;38:110-22.
11. Weng Y.I., Hsu P.Y., Liyanarachchi S., Liu J., Deatherage D.E., Huang Y.W., Zuo T., Rodriguez B., Lin C.H., Cheng A.L., et al. Epigenetic influences of low-dose bisphenol A in primary human breast epithelial cells. Toxicol Appl Pharmacol 2010;248:111-21.
12. Hsu P.Y., Deatherage D.E., Rodriguez B.A., Liyanarachchi S., Weng Y.I., Zuo T., Liu J., Cheng A.S., Huang T.H. Xenoestrogen-induced epigenetic repression of microRNA-9-3 in breast epithelial cells. Cancer Res 2009;69:5936-45.
13. Starlard-Davenport A., Tryndyak V.P., James S.R., Karpf A.R., Latendresse J.R., Beland F.A., Pogribny I.P. Mechanisms of epigenetic silencing of the Rassf1a gene during estrogen-induced breast carcinogenesis in ACI rats. Carcinogenesis 2010;31:376-81.
14. Vona-Davis L., Rose D.P. Angiogenesis, adipokines and breast cancer. Cytokine Growth Factor Rev 2009;20:193-201.
15. Hussain S.P., Harris C.C. Inflammation and cancer: An ancient link with novel potentials. Int J Cancer 2007;121:2373-80.
16. Kang G.H., Lee H.J., Hwang K.S., Lee S., Kim J.H., Kim J.S. Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am J Pathol 2003;163:1551-6.
17. Liggett T., Melnikov A., Yi Q.L., Replogle C., Brand R., Kaul K., Talamonti M., Abrams R.A., Levenson V. Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer 2010;116:1674-80.
18. Issa J.P., Ahuja N., Toyota M., Bronner M.P., Brentnall T.A. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001;61:3573-7.
19. Ushijima T., Asada K. Aberrant DNA methylation in contrast with mutations. Cancer Sci 2010;101:300-5.
20. Kanai Y. Genome-wide DNA methylation profiles in precancerous conditions and cancers. Cancer Sci 2010;101:36-45.
21. Feinberg A.P., Irizarry R.A., Fradin D., Aryee M.J., Murakami P., Aspelund T., Eiriksdottir G., Harris T.B., Launer L., Gudnason V., et al. Personalized epigenomic signatures that are stable over time and covary with body mass index. Sci Transl Med 2010;2:49ra67.
22. Widschwendter M., Jones P.A. DNA methylation and breast carcinogenesis. Oncogene 2002;21:5462-82.
23. Laird P.W. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003;3:253-66. (Pubitemid 37328861)
24. Mohammad Ganji S., Miotto E., Callegari E., Sayehmiri K., Fereidooni F., Yazdanbod M., Rastgar-Jazii F., Negrini M. Associations of risk factors obesity and occupational airborne exposures with CDKN2A/p16 aberrant DNA methylation in esophageal cancer patients. Dis Esophagus 2010;23:597-602.
25. Caldeira J.R., Prando E.C., Quevedo F.C., Neto F.A., Rainho C.A., Rogatto S.R. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer 2006;6:48.
26. Fackler M.J., McVeigh M., Evron E., Garrett E., Mehrotra J., Polyak K., Sukumar S., Argani P. DNA methylation of RASSF1A, HIN-1, RARbeta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int J Cancer 2003;107:970-5.
27. Feng W., Shen L., Wen S., Rosen D.G., Jelinek L., Hu X., Huan S., Huang M., Liu J., Sahin A.A., et al. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 2007;9:R57.
28. Herman J.G., Merlo A., Mao L., Lapidus R.G., Issa J.P., Davidson N.E., Sidransky D., Baylin S.B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525-30.
29. Krassenstein R., Sauter E., Dulaimi E., Battagli C., Ehya H., Klein-Szanto A., Cairns P. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res 2004;10:28-32. (Pubitemid 38114158)
30. Lehmann U., Länger F., Feist H., Glöckner S., Hasemeier B., Kreipe H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 2002;160:605-12. (Pubitemid 34160338)
31. Lewis C.M., Cler L.R., Bu D.W., Zöchbauer-Müller S., Milchgrub S., Naftalis E.Z., Leitch A.M., Minna J.D., Euhus D.M. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk. Clin Cancer Res 2005;11:166-72. (Pubitemid 40081117)
32. Mehrotra J., Vali M., McVeigh M., Kominsky S.L., Fackler M.J., Lahti-Domenici J., Polyak K., Sacchi N., Garrett-Mayer E., Argani P., et al. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin Cancer Res 2004;10:3104-9.
33. Lippone P., Saarelainen E., Ji H., Aaltomaa S., Syrjanen K. Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer. J Pathol 1994;174:101-9.
34. Tao M.H., Shields P.G., Nie J., Millen A., Ambrosone C.B., Edge S.B., Krishnan S.S., Marian C., Xie B., Winston J., et al. DNA hypermethylation and clinicopathological features in breast cancer: The Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Treat 2009;114:559-68.
35. Jeronimo C., Usadel H., Henrique R., Oliveira J., Lopes C., Nelson W.G., Sidransky D. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 2001;93:1747-52.
36. Eads C.A., Danenberg K.D., Kawakami K., Saltz L.B., Blake C., Shibata D., Danenberg P.V., Laird P.W. MethyLight: A high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
37. Marsit C.J., McClean M.D., Furniss C.S., Kelsey K.T. Epigenetic inactivation of the SFRP genes is associated with drinking, smoking and HPV in head and neck squamous cell carcinoma. Int J Cancer 2006;119:1761-6.
38. James P.T., Leach R., Kalamara E., Shayeghi M. The worldwide obesity epidemic. Obes Res 2001;9:228S-33S.
39. Santen R.J., Allred D.C., Ardoin S.P., Archer D.F., Boyd N., Braunstein G.D., Burger H.G., Colditz G.A., Davis S.R., Gambacciani M., et al. Postmenopausal hormone therapy: An Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(suppl 1):s1-s66.
40. McCourt C.K., Mutch D.G., Gibb R.K., Rader J.S., Goodfellow P.J., Trinkaus K., Powell M.A. Body mass index: Relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer. Gynecol Oncol 2007;104:535-9.
41. Peters I., Vaske B., Albrecht K., Kuczyk M.A., Jonas U., Serth J. Adiposity and age are statisticaly related to enhanced RASSF1A tumor suppressor gene promoter methylation in normal autopsy kidney tissue. Cancer Epidemiol Biomarkers Prev 2007;16:2526-32.
42. Slattery M.L., Curtin K., Sweeney C., Levin T.R., Potter J., Wolff R.K., Albertsen H., Samowitz W.S. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer 2007;120:656-63. (Pubitemid 44969038)
43. Ye C., Shrubsole M.J., Cai Q., Ness R., Grady W.M., Smalley W., Cai H., Washington K., Zheng W. Promoter methylation status of the MGMT, hMLH1, and CDKN2A/p16 genes in non-neoplastic mucosa of patients with and without colorectal adenomas. Oncol Rep 2006;16:429-35.
44. Kamei Y., Suganami T., Ehara T., Kanai S., Hayashi K., Yamamoto Y., Miura S., Ezaki O., Okano M., Ogawa Y. Increased expression of DNA methyltransferase 3a in obese adipose tissue: Studies with transgenic mice. Obesity (Silver Spring) 2010;18:314-21.
45. Campión J., Milagro F.I., Goyenechea E., Martínez J.A. TNF-alpha promoter methylation as a predictive biomarker for weight-loss response. Obesity (Silver Spring) 2009;17:1293-7.
46. Van Driel L.M., Eijkemans M.J., De Jonge R., De Vries J.H., Van Meurs J.B., Steegers E.A., Steegers-Theunissen R.P. Body mass index is an important determinant of methylation biomarkers in women of reproductive ages. J Nutr 2009;139:2315-21.
47. Choi S.W., Mason J.B. Folate status: Effects on pathways of colorectal carcinogenesis. J Nutr 2002;132:2413S-8S.
48. Wijekoon E.P., Hall B., Ratnam S., Brosnan M.E., Zeisel S.H., Brosnan J.T. Homocysteine metabolism in ZDF (type 2) diabetic rats. Diabetes 2005;54:3245-51.